Overview

The Efficacy of 10-day or 14-day Course of Bismuth-containing Quadruple Therapy:A Randomized Clinical Trial

Status:
Not yet recruiting

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of Tegoprazan bismuth-containing quadruple eradication therapy at 6 weeks after treatment, subjects underwent another 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.

Phase:

Phase 4

Details

Lead Sponsor:

Shandong University

Collaborators:

Linyi People's Hospital
Weifang Medical University

Treatments:

Bismuth